De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control " always " matter?

被引：0
|
作者：
Lorini, L. [1 ,8 ]
Gili, R. [2 ]
Salvestrini, V. [3 ]
Morelli, I. [4 ]
Smussi, D. [5 ]
Petrelli, F. [6 ]
Bonomo, P.
Bossi, P. [1 ,7 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Via Manzoni 56, I-20089 Milan, Italy
[2] IRCCS Osped Policlin San Martino, Med Oncol Unit, I-16132 Genoa, Italy
[3] Univ Florence, Radiat Oncol Unit, Azienda Osped Univ Careggi, Florence, Italy
[4] Univ Florence, Dept Expt & Clin Biomed Sci, Radiat Oncol Unit, Azienda Osped Univ Careggi, Florence, Italy
[5] Univ Brescia, Dept Med & Surg Specialties, Med Oncol Unit, Radiol Sci & Publ Hlth,ASST Spedali Civil, I-25123 Brescia, Italy
[6] ASST Bergamo Ovest, Oncol Unit, Treviglio, Italy
[7] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy
[8] Via Manzoni 56,0282241, I-20089 Rozzano, Italy
来源：
ORAL ONCOLOGY | 2024年 / 152卷
关键词：
De novo metastatic head and neck squamous; cell carcinoma; Radiation; Immunotherapy; Quality of Life; CLINICAL-PRACTICE GUIDELINES; NASOPHARYNGEAL CARCINOMA; RADIATION-THERAPY; OPEN-LABEL; CHEMOTHERAPY; DIAGNOSIS; SURVIVAL; CARE;
D O I：
10.1016/j.oraloncology.2024.106768
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
De novo metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) constitutes 10% of recurrent/metastatic (RM) cases. Radiotherapy (RT) has a crucial role in the treatment of locally advanced HNSCC, however its application on RM diseases is still limited. The advent of immune checkpoint inhibitors (ICIs) improves the survival of RM HNSCC, however median overall survival is still limited. Integration of locoregional RT with ICIs in de novo metastatic HNSCC represents a promising treatment option. This perspective aims to explore the role of the combination of locoregional and systemic treatment in improving outcomes for synchronous de novo metastatic HNSCC patients and highlights the principal crucial point in decision making.
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Tertiary lymphoid structures in head and neck squamous cell carcinoma
    Zhu, Jing
    Lu, Hui
    Wang, Kongcheng
    Liu, Baorui
    Yan, Jing
    TRANSLATIONAL ONCOLOGY, 2024, 44
  • [22] Bibliometric analysis of immunotherapy for head and neck squamous cell carcinoma
    Cai, Xin-Jia
    Zhang, He-Yu
    Zhang, Jian-Yun
    Li, Tie -Jun
    JOURNAL OF DENTAL SCIENCES, 2023, 18 (02) : 872 - 882
  • [23] Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Results of Polish multicenter observational study
    Rutkowski, Tomasz Wojciech
    Kurczyk, Agata
    Drosik-Rutowicz, Katarzyna
    Kiprian, Dorota
    Debicka, Izabella
    Sierko, Ewa
    Konopka-Filippow, Monika
    Kazmierska, Joanna
    Lukasiewicz-Grella, Monika
    Czastkiewicz-Trawinska, Diana
    Mrochem-Domin, Izolda
    Ryniewicz-Zander, Iwona
    Borysiewicz, Zuzanna
    Chmielowska, Ewa
    Jasiowka, Marek
    Zrebiec-Figura, Monika
    Karpinska, Agnieszka
    Pacholczak-Madej, Renata
    Les, Dominika
    Pietruszka, Agnieszka
    Lasinska, Izabela
    Skladowski, Krzysztof
    INTERNATIONAL JOURNAL OF CANCER, 2025, 156 (05) : 1074 - 1084
  • [24] Multimodality treatment in recurrent/metastatic squamous cell carcinoma of head and neck: current therapy, challenges, and future perspectives
    Pannunzio, Sergio
    Di Bello, Armando
    Occhipinti, Denis
    Scala, Alessandro
    Messina, Gloria
    Valente, Giustina
    Quirino, Michela
    Di Salvatore, Mariantonietta
    Tortora, Giampaolo
    Cassano, Alessandra
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [25] A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Lee, Ji Hyun
    Heo, Seong Gu
    Ahn, Beung-Chul
    Hong, Min Hee
    Cho, Byoung Chul
    Lim, Sun Min
    Kim, Hye Ryun
    CANCER MEDICINE, 2021, 10 (20): : 7012 - 7020
  • [26] Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
    Faraji, Farhoud
    Cohen, Ezra E. W.
    Guo, Theresa W.
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (05) : 1353 - 1358
  • [27] Pharyngotomy in head and neck squamous cell carcinoma: functional and oncological aspects
    Remmert, Carolin
    Mansour, Naglaa
    Hofauer, Benedikt
    Scherer, Elias Q.
    Bas, Murat
    Bier, Henning
    Knopf, Andreas
    ACTA OTO-LARYNGOLOGICA, 2017, 137 (12) : 1281 - 1287
  • [28] Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma
    Oosting, Sjoukje F.
    Haddad, Robert, I
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [29] Platinum resistance and sensitivity in recurrent/metastatic head and neck squamous cell carcinoma
    Horichi, Yuto
    Matsui, Hidetoshi
    Yamamura, Yuta
    Iwae, Shigemichi
    AURIS NASUS LARYNX, 2024, 51 (01) : 132 - 137
  • [30] Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Borel, Christian
    Jung, Alain C.
    Burgy, Mickael
    CANCERS, 2020, 12 (09) : 1 - 19
12345